Elritercept not checked

Takeda · TAK-226 · KER-050

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
6 active
6 in total · 5 in the EU
Targets
—
None known yet

What this is

How it works
A decoy protein that soaks up a signal molecule before it can reach the body's cells.-cept: receptor molecules, native or modified WHO name stem
How it’s given
“Elritercept (TAK-226, KER-050) administered subcutaneously every 4 weeks.”In the company’s words, NCT06499285 on ClinicalTrials.gov
Tested for
Myelodysplastic Syndromes (3 trials), Anemia (2 trials), Myelofibrosis (2 trials), Myelodysplastic Syndrome, Cytopenia
Main trialPhase 3
“The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.”In the company’s words, NCT06499285 on ClinicalTrials.gov
Other names
TAK-226 · KER-050

Other drugs for Myelodysplastic Syndromes

All 96 drugs for Myelodysplastic Syndromes

Coming up6

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 15 Sep 2028 A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Phase 3Recruiting 30 Apr 2029 A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
Phase 3Recruiting 7 Dec 2029 A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Phase 2Recruiting 28 Feb 2028 A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
Phase 2Recruiting 26 Jun 2028 A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes
Phase 2Recruiting 30 Oct 2029 A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Elritercept

Following is part of Solo: you see every change to Elritercept the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in